BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28244637)

  • 1. Blastic transformation of juvenile myelomonocytic leukemia caused by the copy number gain of oncogenic KRAS.
    Osumi T; Kato M; Ouchi-Uchiyama M; Tomizawa D; Kataoka K; Fujii Y; Seki M; Takita J; Ogawa S; Uchiyama T; Ohki K; Kiyokawa N
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy.
    Kato M; Yasui N; Seki M; Kishimoto H; Sato-Otsubo A; Hasegawa D; Kiyokawa N; Hanada R; Ogawa S; Manabe A; Takita J; Koh K
    J Pediatr; 2013 Jun; 162(6):1285-8, 1288.e1. PubMed ID: 23403250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lineage-dependent skewing of loss of heterozygosity (LOH) of KRAS gene in a case of juvenile myelomonocytic leukemia.
    Tokuda K; Eguchi-Ishimae M; Iwabuki H; Kawakami S; Tauchi H; Ishii E; Eguchi M
    Eur J Haematol; 2015 Feb; 94(2):177-81. PubMed ID: 24766281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
    De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
    Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD
    Blood; 2009 Feb; 113(6):1304-14. PubMed ID: 19066392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
    Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
    Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.
    Melo-Cardenas J; Xu Y; Wei J; Tan C; Kong S; Gao B; Montauti E; Kirsammer G; Licht JD; Yu J; Ji P; Crispino JD; Fang D
    Blood; 2018 Jul; 132(4):423-434. PubMed ID: 29844011
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
    Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
    Yoshida N; Doisaki S; Kojima S
    Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic and myeloproliferative disorders of childhood.
    Hasle H
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):598-604. PubMed ID: 27913534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. After 95 years, it's time to eRASe JMML.
    Meynier S; Rieux-Laucat F
    Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Juvenile myelomonocytic leukemia with prominent CD141+ myeloid dendritic cell differentiation.
    Meyerson H; Awadallah A; Blidaru G; Osei E; Schlegelmilch J; Egler R; Abu-Arja R; Ding H
    Hum Pathol; 2017 Oct; 68():147-153. PubMed ID: 28414089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive congenital juvenile myelomonocytic leukemia associated with somatic KRAS p.G13D mutation and concurrent germline IGF1R duplication.
    Kothari A; Hulbert ML; Cottrell CE; Nguyen TT
    Leuk Lymphoma; 2015 Apr; 56(4):1175-8. PubMed ID: 25110823
    [No Abstract]   [Full Text] [Related]  

  • 17. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.
    Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S
    Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular mechanism and treatment of juvenile myelomonocytic leukemia (JMML)].
    Manabe A
    Rinsho Ketsueki; 2012 Aug; 53(8):729-33. PubMed ID: 22975811
    [No Abstract]   [Full Text] [Related]  

  • 20. Concurrent juvenile myelomonocytic leukemia and T-lymphoblastic lymphoma with a shared missense mutation in NRAS.
    Ly B; Modi A; Rogers HJ; Makishima H; Hanna R; Cook JR; Theil KS; Maciejewski JP
    Pediatr Blood Cancer; 2014 May; 61(5):946-8. PubMed ID: 24610751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.